Valneva rises after Lyme disease vaccine study data

Valneva SE

03/09/2025 08:56

** Shares of Valneva VLS.PA are up 5%, paring gains after rising as much as 13%, as the French vaccine maker posted positive data from a Lyme disease vaccine candidate study

** Portzamparc notes 100% seroconversion rate after booster dose and no safety or tolerance issues flagged by the data monitoring committee

** The broker describes the data as "encouraging" ahead of the vaccine's Phase III read-out expected by year-end

 (Reporting by Leo Marchandon)

 ((Leo.marchandon@thomsonreuters.com))